Scott Myers, Chairman, President & Chief Executive Officer
Scott Myers has served as our President and Chairman and Chief Executive Officer since June 2018 and September 2018 respectively. Prior to joining Rainier Therapeutics Scott Myers has more than 20 years of biopharmaceutical industry experience in product development, commercialization and corporate transactions. He was most recently CEO, President and a Director of Seattle-based Cascadian Therapeutics (CASC), an oncology company, until it was acquired by Seattle Genetics in March of 2018. Prior to Cascadian, he was CEO of Aerocrine AB (AERO), a medical device company based in Stockholm, Sweden, and Morrisville, NC, until it was acquired by Circassia, PLC in 2015. Prior to Aerocrine, Scott held senior commercial operations, general management and information management positions for UCB SA, a Belgium based biopharmaceutical company, and Johnson & Johnson. From 2012-2014, Scott was an independent director of Orexo, AB (OREX), a Swedish CNS company. Currently, Scott is an Independent Director and member of the Audit Committee for Harpoon Therapeutics (HARP), a publicly traded Oncology Company focusing on innovative T Cell engaging platforms. Scott is also an Independent Director and member of the Nomination and Governance committee of SelectaBio (SELB), SelectaBio has developed the ImmTOR platform focused on the treatment of Gout and other novel therapies for immune system diseases. Scott earned his BA in biology from Northwestern University and his MBA from The University of Chicago Booth School of Business.
Fouad Azzam, Ph.D., MBA
Fouad Azzam, Ph.D., MBA, joined LSP in 2007. He became a General Partner of the firm in that same year. Fouad’s prime focus and responsibility within LSP is to invest in unlisted securities and manage the firm’s North American operations. Prior to joining LSP, Fouad was the Managing Director of Eastman Ventures, the investment arm of Eastman Chemical Company, where he built-up its Healthcare and Advanced Materials practice. In his role as Managing Director, he was responsible for numerous early- and late-stage investments across the US & Europe. Fouad brings a wealth of investment expertise to the LSP team. Prior to his role at Eastman Ventures, Fouad held senior leadership positions at Eastman Chemical including roles in Innovation, Corporate Strategy, Corporate Development (M&A) and New Business Development. His career also includes business, operating, and technology roles at Occidental Chemical and BFGoodrich. Among others, Fouad is currently a Director at Illuminoss Medical, a company championing minimally invasive solutions for the stabilization and treatment of bone fractures. Fouad’s academic credentials include a Master’s degree and PhD in Chemical Engineering from the University of Akron in Ohio. In addition, Fouad obtained an MBA in Finance & Strategy from the University at Buffalo in New York. Fouad lives in the greater Boston area with his wife and two children.
Joël Jean-Mairet, Ph.D.
Joël Jean-Mairet, Ph.D., is managing partner and co-founder of Ysios Capital. Previously, he co-founded Glycart Biotechnology AG in 2001 and was its CEO until the company was successfully sold to F. Hoffmann La-Roche four years later. Glycart Biotechnology was the originator of Gazyva ® approved for B-CLL by the FDA as first-ever breakthrough therapy. He holds an MS in Biotechnology and a Ph.D. from the Swiss Federal Institute of Technology (ETH) in Zurich.
Joël is currently on the boards of directors of AM-Pharma B.V., Aura Biosciences Inc, Sanifit S.L. and Chairman of Inbiomotion S.L. He has been Chairman of the board of Cellerix (now Tigenix NYSE Euronext TIG), on the boards of Medlumics S.L. and Dermaluics S.L. and board observer at Biovex, Inc. (now Amgen). Joël has earned numerous awards, including the Gold Medal of Wall Street Journal’s Europe Innovation Award in 2001.
David Kabakoff, Ph.D.
David joined Sofinnova as an Executive Partner in 2007. He represents Sofinnova as the Chairman of NextCure (NASDAQ:NXTC), and as Director of Antiva Biosciences, Dauntless Pharmaceuticals, and Principia Neurana. He also serves as Chairman of Lineagen and as a Director of Castle Biosciences (NASDAQ:CSTL) and bioTheranostics. Previously he served as the Chairman of both Trius Therapeutics and Amplimmune, and as a Director of InterMune and Allylix.
Prior to Sofinnova, David spent almost 30 years in industry leading technology and product development programs in the pharmaceutical, biopharmaceutical, and drug delivery fields. David co-founded Salmedix, a developer of cancer drug treatments, and served as the company’s Chairman and Chief Executive Officer. In June 2005, he negotiated the acquisition of Salmedix by Cephalon. David also held the positions of Executive Vice President of Dura Pharmaceuticals and President and Chief Executive Officer of Spiros Development. Earlier, David was also employed as Chief Executive Officer of Corvas International and held senior executive positions with Hybritech.
David received his PhD from Yale University and his BA from Case Western Reserve University.
David Lacey, M.D., Board Observer
Dr. David Lacey, formerly Senior Vice President of Discovery Research at Amgen, possesses over 20 years of scientific and senior leadership experience within the life sciences, focused on creating new medicines to make a difference in the lives of patients worldwide. During his tenure at Amgen, Dr. Lacey led an organization of more than 1200 scientists across a portfolio of drug discovery and development programs in the therapeutic areas of hematology/oncology, inflammation, metabolic disorders, and neuroscience. Dr. Lacey currently serves as a Board member for Nurix Inc., Atreca, and Inbiomotion SL, and acts as an advisor to a number of academic institutions, biotechnology companies, and is a Venture Partner at Ysios Capital.
Christian M. Richard, M.S, MBA
Christian Richard joined Tekla Capital Management in March of 2015 as Senior Vice President of Research. Previously, he was a Partner/Head of Research for Merlin Biomed Private Equity/Merlin Nexus for 12 years. Merlin Nexus is a cross-over life sciences fund focused on negotiated transactions in both late-stage private and public companies. Prior to Merlin Nexus, he spent almost five years in the Allergy/Immunology Group at the Schering-Plough Research Institute. He has a BS in Cellular and Molecular Biology from Purchase College and both an MS in Biochemistry and an MBA in Finance from NYU.
Michael Sjöström, CFA, Board Observer
Michael founded Sectoral Asset Management in Montreal with Jérôme Pfund in 2000. Michael has managed Sectoral’s biotech strategy from 1994 until 2014. He has been part of Sectoral’s private equity team since its inception in 2008. In 2018, after serving as CIO for 17 years, he joined the company’s Private Equity team as Senior Partner.
Michael graduated in 1987 from the University of St.Gallen with an MBA in Finance and Economics. He obtained his CFA charter in 1996.
Prior to establishing Sectoral, he worked for two Swiss banks and, in 1993, joined Pictet & Cie in Geneva as a pharmaceutical analyst. From 1994 until October 2000, he was the Portfolio Manager of Pictet Fund-Biotech and head of the pharma analyst team.
Mårten Steen, M.D., Ph.D.
Dr. Mårten Steen is a partner at HealthCap, and previously worked with global business development at Merck Serono, focusing on both product and technology licensing. Prior to Merck Serono, he was a medical associate with HealthCap. Mårten is a Medical Doctor trained at Lund University. He has pursued research in the field of protein chemistry and coagulation at Lund University and Novo Nordisk, rendering him a Ph.D. in Clinical Chemistry in 2003. He is the author of 16 scientific papers and published in peer-reviewed journals. He has also a B.Sc. degree in Business Administration from the Lund University School of Economics and Management. He serves on the board of Wilson Therapeutics AB, Immune Targeting Systems Ltd, and deputy member of the board of Nordic Nanovector AS. He previously served on the board of Ultragenyx Inc (RARE) and FerroKin Biosciences prior to its acquisition by Shire.
Thijs Cohen Tervaert, M.D., Board Observer
Thijs Cohen Tervaert is a Director at INKEF Capital. Thijs currently serves on the board of ViCentra, Castor, Aidence, Audion Therapeutics and Rainier Therapeutics. Prior to INKEF, Thijs was a strategy consultant at the Boston Consulting Group with a focus on health care and technology. He worked on projects for pharmaceutical companies, hospitals and insurers. Thijs is a medical doctor and graduated at Leiden University. He has also co-authored several scientific papers.
Joseph Turner, Independent Director
Joe Turner has been an active board member for a number of private and public biopharmaceutical companies. Joe previously served on the Board of Directors of several publicly-held biotechnology companies: Allos Therapeutics, Inc. (acquired by Spectrum Pharmaceuticals), QLT, Inc., SGX Pharmaceuticals, Inc., (acquired by Lilly), Alexza Pharmaceuticals, Inc. (acquired by Grupo Ferrer), Corcept Therapeutics, Inc., Kythera Biopharmaceuticals (acquired by Allergan), and Sophiris Bio. . Joe has also served on the Board of Directors of privately-held biotechnology companies: NovaCardia, Inc. (acquired by Merck & Co., Inc.), Sequel Pharmaceuticals, Inc., Nora Therapeutics and ApopLogic Pharmaceuticals, Inc. Joe is currently a member of the Board of Directors of miRagen Therapeutics. Joe also currently serves on the Board of Managers of Swarthmore College.
Previously, Joe was the Senior Vice President of Finance and Administration and Chief Financial Officer at Myogen, Inc. from 1999 until its acquisition by Gilead Sciences, Inc., in November 2006. Prior to Myogen, he served as Vice President, Finance and Chief Financial Officer at Centaur Pharmaceuticals, Inc. from 1997 to 1999 and as Vice President, Finance and Chief Financial Officer of Cortech, Inc. from 1992 to 1997. From 1979 to 1991, Joe worked at Eli Lilly and Company, where he held a variety of financial management positions both within the United States and abroad. Joe received his M.B.A. from the University of North Carolina at Chapel Hill, an M.A. in Molecular Biology from the University of Colorado at Boulder and a B.A. in Chemistry from Swarthmore College.